Prednisone Active Not Recruiting Phase 2 Trials for High Risk Prostate Cancer / Adenocarcinoma, Prostate / Prostate Cancer Treatment

Active Not RecruitingTreatment2 IdentifierTitleDrugs
NCT02268175Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
NCT02985957Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
NCT01940276Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer
NCT02903368Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
NCT01717053Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
NCT01309672S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
NCT02685267Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer
NCT01254864Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies